SITE008-0247

SITE008 (KOR) › SITE008-0247

SITE008-0247

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2026-06-19

enrolled

AEs

3

Serious

1

Dropout signal

–

Adverse events

3

Grade 1 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-03-10 (study day 75); relationship: not assessed

mild assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-07 (study day 44); relationship: not assessed

moderate assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-07 (study day 13); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Data queries

0

No data queries. Open queries would appear here for this patient.